BPC-157 + TB-500 (Wolverine Stack) Reconstitution + Dosage Calculator and Injury Protocol Guide

The Wolverine Stack: BPC-157 & TB-500 Dosage

BPC-157 and TB-500 use different dose scales and schedules: BPC-157 is dosed daily in micrograms, while TB-500 is dosed 2-3x weekly in milligrams. Separate vials preserve that distinction. A premixed vial reduces handling but fixes the ratio and puts both peptides on one schedule.

The two peptides target different repair bottlenecks. BPC-157 supports new capillary growth and blood supply; TB-500 supports the movement of repair cells that organize new tissue.¹ ² The stack pairs perfusion with cell migration.

No human trial has tested the combination. BPC-157 evidence is predominantly preclinical, and the human record is uncontrolled apart from one randomised placebo-controlled trial in ulcerative colitis that was too small to detect the difference it observed.³ The Phase 1 human safety data belongs to full-length TB-4, not automatically to the TB-500 fragment.⁴ The protocol comes from component mechanisms rather than a controlled trial of the pair.

For the mechanism deep-dives, see the standalone guides: BPC-157 and TB-500 / TB-4. For the narrative injury-recovery walkthrough, see the Wolverine Stack guide.

Calculating Dosage & Reconstitution

The vial format determines the calculation:

• Individual vials are reconstituted separately and retain independent schedules; this is preferred for the protocol
• A combined vial / blend needs one reconstitution, but every draw delivers both peptides at the supplied ratio and couples their schedules

Every case below uses the same formula:

V_draw = D × V_waterM

V_draw is the syringe draw (mL), $D$ the target dose, V_water the BAC water added (mL), and $M$ the vial mass of the compound being solved for. Match the units of $D$ and $M$: both mg, or both mcg.

Path 1: individual vials

Reconstitute each vial separately, then dose on its own schedule.

BPC-157: 250-500 mcg daily

Reconstitute BPC-157 on the dilute side. The marketed 2,000 mcg/mL strength is roughly 1,000x the concentration at which the only fine-grained concentration-response curve for this peptide reverses direction, so the volumes below target 1,000 mcg/mL or lower. That is an argument about concentration, not about where the dose goes.

V_draw = 500 mcg × 5 mL5000 mcg = 0.5 mL = 50 units on a U-100 syringe

The 15 mg and 20 mg vials often ship with smaller default volumes, 5 mL and 8 mL, which land at 3,000 and 2,500 mcg/mL. Both sit well above the 1,000 mcg/mL target and read on the syringe in fractions of a unit. The larger volumes above fix both problems at once.

TB-500: 1-2.5 mg 2-3x weekly

TB-500 goes the other way — the smallest practical volume rather than the dilute mix BPC-157 gets. Both common vial sizes give 5 mg/mL:

V_draw = 2 mg × 2 mL10 mg = 0.4 mL = 40 units on a U-100 syringe

A 10 mg vial supplies 10 doses at 1 mg, five at 2 mg, or four at 2.5 mg.

On overlap days, BPC-157 and TB-500 are sometimes co-drawn because their solutions are pH-compatible. That convenience does cost BPC-157 its dilution, since a co-draw delivers both at whatever the TB-500 vial concentration is. NAD+ requires a separate syringe and site because its acidity can degrade peptides on contact.

Path 2: combined blend vial

A blend vial holds both peptides at a fixed mass ratio. One reconstitution sets both doses, and every draw delivers the pair on one schedule.

Standard 1:1 blends

Equal-mass blends are commonly labeled 5/5 or 10/10. A "10 mg Wolverine Stack" contains 5 mg of each peptide; a "20 mg" vial contains 10 mg of each.

Because the ratio is 1:1, a daily 0.1 mL draw puts BPC-157 at 500 mcg but delivers 0.5 mg TB-500 every day rather than 1-2.5 mg on 2-3 days. Seven daily 0.5 mg draws total 3.5 mg TB-500 per week, inside the 2.0-7.5 mg envelope but built from doses below the 1 mg floor. Separate vials (Path 1) avoid the coupling.

Custom blends

When the masses are unequal, one peptide becomes the dose anchor and the other scales with the vial ratio. This is the same anchor math used by the KLOW calculator.

Example — a 10 mg BPC-157 / 5 mg TB-500 vial (a 2:1 blend), anchored to 500 mcg BPC-157, reconstituted in 2 mL:

V_draw = 0.5 mg × 2 mL10 mg = 0.1 mL = 10 units

That same 0.1 mL draw also delivers 250 mcg TB-500 — half the BPC-157 dose, by the 2:1 ratio.

The calculator above solves either path, individual vials or a blend at any ratio, for any vial size or target dose.

Dosing Protocol

The derived position for BPC-157 starts at 250 mcg. Both routes are defensible, and IM is the one with PK data. TB-500 doses are distributed across the week to a 4-6 mg weekly target, with a full envelope of 2.0-7.5 mg; a conservative first cycle is 1-1.5 mg twice weekly, or 2-3 mg per week. Above 6 mg/week exceeds both veterinary anchors, which makes it a deliberate exception rather than a default. NAD+ is a conditional add-on for chronic, post-surgical, or energy-limited recovery.

Cycle length: 4-6 weeks for both peptides, then stop and assess.

Weekly and course totals

The weekly total for BPC-157 is 1.25-3.5 mg, the floor being 250 mcg on five days and the ceiling 500 mcg every day. The course total is 5.0 mg at four weeks or 7.5 mg at six on the low end. Those totals are the reason the duration sits where it does: twelve weeks at 500 mcg daily is a 42 mg course, nothing in the evidence supports the top of that range, and no dose-response curve was ever established.

TB-500's weekly band rests on two veterinary anchors that disagree by 2.6x. An equine protocol scales to 2.29 mg/week for a 70 kg human; back-calculation from a 5 mg greyhound dose gives 5.91 mg/week. No efficacy endpoint anchors the band in humans.

Cycle structure

Both peptides hold a steady dose across the course. Neither carries a loading phase, and neither tapers into maintenance.

At 2-3 doses weekly, 2 mg per dose reaches the 6 mg/week ceiling on a three-day schedule, so 2.5 mg fits two dosing days rather than three.

Escalation, for non-responders only

A 500-750 mcg daily tier exists for non-responders. What it tests is whether the labelled dose was ever actually received, because purity is not fill accuracy and an unverified vial may hold well under label. The tier is one step rather than the first rung of a ladder, and a step that changes nothing should end the course.

Why BPC-157 is daily and TB-500 is not

BPC-157 delivers a signal. A small daily dose triggers repair cascades, including new blood vessel formation and repair-cell migration, that keep running after the peptide itself clears.¹ The signalling is catalytic rather than stoichiometric — a switch, not a pool — which is why a short plasma half-life does not undercut a persistent downstream effect.

TB-500 follows a concentration-dependent mechanism rather than a small daily signal.² The dosing is therefore milligram-scale on 2-3 days a week at a steady 1-2.5 mg, holding that dose across the course instead of front-loading and tapering. Doses below 1 mg may not reach the proposed concentration threshold.

Weekly schedule

Each row totals inside the locked weekly bands: BPC-157 at 3.5 mg, and TB-500 at 5 mg on the two-day schedule or 6 mg on the three-day one. Specific weekdays matter less than distributing the TB-500 doses across the week. NAD+ remains in a separate syringe and site.

Injection routing

Deliver to the target compartment where a route reaches it. For subq, that means injecting near the injury when the site is easy and safe to reach.

For BPC-157 the basis is the human record rather than a local depot. Every human cohort ever dosed with this molecule received it into or onto its target: intra-articular into the knee, intravesical into the bladder wall, rectal enema onto colonic mucosa. The only systemic exposure in the entire human ledger is a two-person intravenous safety pilot with no indication and no efficacy endpoint.

Two limits belong with that. No human study has used the subcutaneous route at all, and nobody has compared near-injury against distal injection in any species, so near-injury subq follows the direction of the human evidence rather than being proven by it. The rat distribution finding of skeletal muscle below plasma an hour after IM dosing rules out a lasting subq depot, which is a narrower claim than where to deliver, and it is a rodent measurement in uninjured tissue at one timepoint.

TB-500's argument is different. The fragment carries a small positive charge patch, and tendon, cartilage and disc are built on strongly negatively charged matrix, so the proposal is that it is drawn in and held rather than washed out. That is a hypothesis with a clean falsification test — compare near-injury against distal placement and measure tissue retention — not an established mechanism, and not engineered injury-seeking. Near-injury is defensible and worth the small effort on that basis.

For hard-to-reach injuries such as spine or deep hip, abdomen or thigh works. See Where to Inject Peptides for the full breakdown.

How the Stack Works

Healing stalls when two things fail at once: the blood supply to the injury closes down, and the repair cells that rebuild tissue cannot move into position. The stack assigns one peptide to each problem.

BPC-157: blood supply

BPC-157 is a 15-amino-acid fragment of a protein found in gastric juice. Preclinical research associates it with new capillary growth, nitric oxide signaling, and the FAK-paxillin pathway involved in repair-cell attachment and migration.¹ ⁶ These mechanisms provide the rationale for its use as the perfusion component of the stack.

TB-500: repair-cell movement

TB-500 is usually the thymosin beta-4 fragment 17–23, the short sequence tied to repair-cell movement. Every cell has internal scaffolding made of actin; TB-500 supports the actin-side signal repair cells use to migrate into damaged tissue (actin-binding repair signal).² These proposed roles are the rationale for pairing it with BPC-157.

One caution on identity: TB-500 (the fragment) and full-length TB-4 (43 amino acids) are related but not interchangeable, and product labels blur the two routinely.⁷ The stronger anti-scarring and tissue-remodeling claims come from full-length TB-4 research, not the isolated fragment. If scar remodeling is the goal, confirm the molecular weight on the certificate of analysis: around 800 Da is the fragment, around 4,900 Da is full-length. See the TB-500 guide for the full distinction.

Why the two mechanisms are paired

The evidence supports pairing the mechanisms, but not deterministic outcomes for every missing or combined component. Preclinical BPC-157 work supports blood-vessel and repair-cell signaling, while TB-500/TB-4 research supports cell migration.¹ ² Neither evidence base establishes that BPC-157 alone causes scar or adhesions or that the pair produces "organized tissue reconstruction" in humans.

In one rat model, combined BPC-157 + TB-4 restored contractile function earlier than either compound alone.⁸ That result supports further study of the pairing; it does not establish a human tissue outcome.

What the Wolverine Stack Is Not For

The stack clears a coupled perfusion-and-migration bottleneck: BPC-157 restores blood flow, while TB-500 supports repair-cell movement. That pairing fits tendon, ligament, muscle, fascia, joint capsule, and scar or connective tissue. It does not address tissues governed by different repair biology.

Bone and fracture repair. Mineralization, callus formation, and bone-matrix remodeling set the pace. Neither peptide directly supplies that mechanism.

Isolated cartilage. Cartilage has no blood supply to restore. Chondrocyte and matrix biology govern repair, and a systemic SubQ stack does not target a focal joint surface. Cartalax is the cartilage-specific option covered elsewhere in the library.

Peripheral nerve. Axonal regrowth depends on Schwann-cell and neurotrophic signaling rather than perfusion alone. ARA-290 is the nerve-repair compound covered by PeptideFox.

Central nervous system. Stroke and traumatic brain injury require blood-brain-barrier access and CNS-specific signaling. BPC-157 and TB-500 are peripheral repair peptides; Semax is the CNS-active option covered by PeptideFox.

Both peptides show isolated preclinical signals in spinal-cord-injury models. That evidence supports describing the Wolverine Stack as a peripheral soft-tissue protocol, not claiming the compounds are inactive in every other tissue. Bone, cartilage, peripheral nerve, and CNS repair remain outside the protocol’s mechanism-led scope.

When to Add NAD+

BPC-157 + TB-500 cover blood supply and cell movement, the two layers most soft-tissue injuries need first. NAD+ is the first add when those mechanisms are working but progress stalls, because repair cells still need enough cellular energy to build collagen and remodel tissue.

NAD+ from the start fits a chronic injury of six months or longer, post-surgical recovery, high training load, or recovery that feels systemically draining. The protocol uses 50–200 mg IM about three times weekly in a separate syringe and site. NAD+ is acidic (pH 3–4), degrades peptides on contact, and can sting; room-temperature solution and a slow push reduce that discomfort.

The other layers are conditional. GHK-Cu fits poor load-bearing quality that points to collagen organization as the remaining bottleneck. KPV fits inflammation that keeps cycling back, such as swelling that returns after moderate activity despite four or more weeks; it pre-empts the inflammation switch (NF-κB).⁹

For all three layers at once, the Injury Recovery Protocol is the cleaner path than bolting compounds onto this stack one at a time.

Tell FoxAI about your injury and it builds the right protocol→

Phenotype Considerations

Chronic injuries of six months or longer. Established scar tissue and adapted blood-supply patterns can add bottlenecks beyond the vascular and migration layers this stack addresses. NAD+ starts with the stack, and the cycle runs to the full six weeks before the stop-and-assess point.

Post-surgical recovery. The convention defers the stack until the initial clotting window has settled, usually two weeks, unless the surgical team directs otherwise. Early new blood-vessel formation can complicate fresh surgical healing.

GLP-1 use or caloric deficit. Repair draws on energy and protein that a deficit restricts. NAD+ moves from a conditional layer to a first-line add, and the protein floor in Supporting Factors carries more weight.

WADA-tested athletes. TB-500 is prohibited, and BPC-157 is classified under WADA S0. Both have detectable metabolites, so the stack is incompatible with tested competition.

Supporting Factors

Peptides provide the repair signal. The raw materials come from nutrition and loading.

These inputs supply repair substrates and controlled mechanical loading. Peptide use does not replace physical therapy; new collagen still requires directional load to organize.

When Progress Stalls

The shape of the stall is more informative than an automatic dose increase.

Early improvement that levels off. The vascular and migration bottlenecks may have cleared while energy, collagen quality, or inflammation became rate-limiting. The matching layer is NAD+, GHK-Cu, or KPV.

Tissue warmth with falling energy. The repair signal is present, but the energy supply is lagging. Review protein and sleep first, then add or tighten NAD+.

No change by week 3. Product identity, injection technique, and storage come before dose escalation. Reconstituted vials should remain refrigerated and protected from light; degradation can erase the expected response.

Scar remodeling does not improve. Confirm vial identity. The anti-scarring evidence belongs to full-length TB-4, not the TB-500 fragment; a mislabeled fragment cannot carry that claim.⁷

Safety & Considerations

Active cancer or malignancy within two years. Both peptides promote new blood-vessel formation, which could theoretically support an existing tumor’s blood supply. Active treatment is a contraindication, and the first two years after remission require caution.

Pregnancy or breastfeeding. Neither peptide has safety data for these populations.

Proliferative retinopathy. New blood-vessel formation may worsen the underlying pathology.

Recent or planned surgery. The stack waits until the initial clotting window has settled unless the surgical team directs otherwise.

Therapeutic anticoagulation, active autoimmune disease, or concurrent corticosteroids. These situations add specific interaction risks. Corticosteroids oppose the repair mechanisms the stack is meant to drive, while TB-500 changes immune-cell behavior in ways that may interact with autoimmune disease.

Conventional alternatives include physical therapy, NSAIDs, and corticosteroid injections. Each targets a different part of injury management and carries a different evidence and risk surface.

Regulatory & Legal Status

Neither BPC-157 nor TB-500 is FDA-approved for any use, and neither is an approved injury therapy. Regulatory status does not establish either safety or therapeutic failure.

BPC-157 was removed from FDA Category 2 on 22 April 2026 by nominator withdrawal, not because a safety concern was resolved. Then on 23 July 2026 the Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157 to the 503A Bulks List, against FDA’s own staff, who had recommended against listing. The same meeting reached the same result separately for TB-500.

Operative status is recommended for listing, pending FDA action. A committee recommendation is not a rule; notice-and-comment rulemaking follows and can take over a year. This is an access-pathway question rather than therapeutic approval, and not a safety or efficacy verdict. Compounding still constitutes unapproved new drug manufacturing under the FD&C Act, the floor that applies to all non-monograph peptides, but the Category-2 prohibition by name is gone.

Two scoping facts belong with the decision. The evaluation covered ulcerative colitis only; tendonitis was excluded for insufficient nomination information, so a colitis decision is being widely read as a verdict on a musculoskeletal compound. The vote count is also contested across the source documents, so no tally is quoted here as primary-sourced. The Wolverine Stack as a combination has not been evaluated by the FDA.

WADA (sport) status. Both are prohibited at all times, in and out of competition. BPC-157 is classified under S0 (non-approved substances); TB-500 falls under S2 (peptide hormones and growth factors). Metabolites of both are detectable on testing, so the stack is not usable for any drug-tested athlete.

What Evidence Exists

BPC-157. A 2025 systematic review covers 36 studies: 35 preclinical and one clinical study with 12 patients.³ New blood-vessel formation, nitric oxide signaling, and FAK-paxillin repair-cell migration are well characterized. There is no published receptor binding constant and no characterised minimum effective concentration, so dose decisions rest on preclinical envelopes rather than target-engagement thresholds.

A controlled trial does exist. Ruenzi 2005 was a multicentre randomised double-blind placebo-controlled Phase 2 in ulcerative colitis, 53 randomised, 80 mg/day enema for 14 days, published only as a meeting abstract. Its between-group confidence interval spans zero and is wider than the point estimate, and the power for the observed difference is roughly 16%, so the trial was too small to detect the difference it observed — uninformative rather than null.

A hamstring registration (NCT07437547, Peking University Shenzhen) is registered but provenance-flagged: it sits in a cluster of eight registrations from one registrant sharing one site, one phone and one email, three of which self-declare as fictional, example or mock records. Enrollment is estimated and no dose is disclosed anywhere in the record. What is not established is that the record is fake, since it does not self-declare, has a real named hospital and a clinically literate protocol. Treat it as registered-unverified.

TB-500 and TB-4. Full-length TB-4 has human data from corneal-healing Phase 2/3 trials, cardiac and wound programs, and Phase 1 safety work.⁴ Those instruments studied the full-length protein. Their findings do not transfer automatically to the TB-500 fragment, which makes vial identity part of the evidence claim.

The combination. No human trial has tested the Wolverine Stack. One rat model found that BPC-157 + TB-4 restored function earlier than either compound alone.⁸ The human protocol remains a mechanism-led, community-derived construction rather than a measured combination outcome.

FAQ

Related Topics

• BPC-157 + TB-500 Calculator — Reconstitution and per-dose math for both vials
• Wolverine Stack Guide — The narrative injury-recovery walkthrough and weekly timeline
• Injury Recovery Peptide Protocol — Five-compound framework adding NAD+, GHK-Cu, and KPV
• BPC-157 Guide — Standalone dosing, oral vs injectable, pharmacokinetics
• TB-500 / TB-4 Guide — Fragment vs full-length, certificate-of-analysis verification
• NAD+ Guide — Cellular energy support for stalled healing
• KLOW Dosage Calculator — Four-peptide blend that includes BPC-157 and TB-4 for skin and tissue repair
• Peptide Calculator — General-purpose reconstitution and dosing calculator
• Where to Inject Peptides — Near-injury vs systemic injection routing

References

¹ BPC-157 angiogenic signaling — VEGFR2-Akt-eNOS activation, nitric oxide bioavailability, endothelial sprouting, anti-cytokine modulation: PMC8275860

² TB-500 / TB-4 G-actin sequestration — actin-monomer binding maintains the reserve pool repair cells draw on for migration; mass-action pharmacodynamics favor bolus dosing: PubMed 12581423

³ BPC-157 systematic review — 36 studies (35 preclinical, 1 clinical with 12 patients); VEGF upregulation, eNOS activation, FAK-paxillin cascade. Vasireddi N et al. "Emerging Use of BPC-157 in Orthopaedic Sports Medicine." HSS J. 2025. PMC12313605

⁴ TB-4 Phase 1 safety — 84 healthy volunteers tolerated recombinant thymosin beta-4 up to 25 μg/kg daily for 10 days with no serious adverse events. Wang D et al. Ann Transl Med. 2021;9(15):1232. PMC8419156

⁵ TB-4 local-versus-systemic tissue concentration — free systemic TB-4 at a matched total dose produced no functional improvement versus a locally-targeted formulation; systemic dilution dropped tissue concentration below threshold: PMC5396927

⁶ BPC-157 tendon outgrowth — FAK-paxillin signaling promotes repair-cell outgrowth and migration. Chang et al. J Appl Physiol. 2011. PubMed 21030672

⁷ TB-4 / TB-500 mislabeling — documented bidirectional mislabeling between full-length TB-4 (43 aa) and the TB-500 fragment (residues 17–23) in marketed products. Esposito M et al. Drug Test Anal 2012. PubMed 22962027

⁸ Combined BPC-157 + TB-4 — combined administration restored contractile function earlier than either compound alone. Rahman OF et al. "Therapeutic Peptides in Orthopaedics." J Am Acad Orthop Surg Glob Res Rev. 2026;10(1). PMC12753158

⁹ KPV NF-κB inhibition — blocks nuclear translocation of NF-κB, suppresses inflammatory transcription while preserving normal immune signaling: PubMed 18061177

¹⁰ Collagen supplementation — systematic review of collagen peptide effects on synthesis and recovery; pre-exercise timing. Kirmani BH et al. Amino Acids. 2021. PMC8521576

¹¹ BPC-157 and tumor risk — narrative review of regeneration versus cancer risk; preclinical data suggest anti-tumorigenic properties in some contexts. McGuire FP et al. "Regeneration or Risk?" Curr Rev Musculoskelet Med. 2025;18(12):611–619. PMC12446177

This content is for educational purposes only. BPC-157 and TB-500 are not FDA-approved injury therapies. No human trial has tested the combination; the protocols above come from component mechanisms and community observation. Active cancer, autoimmune disease, and medications that affect immune function or coagulation add risks that require individual clinical assessment.